Publicaciones en las que colabora con J. Villanúa (10)

2022

  1. Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors (Scientific Reports, (2018), 8, 1, (12746), 10.1038/s41598-018-30836-5)

    Scientific Reports

2020

  1. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Liquid biopsy in glioblastoma: Opportunities, applications and challenges

    Cancers, Vol. 11, Núm. 7

2018

  1. Indirect costs associated with glioblastoma: Experience at one hospital

    Neurologia, Vol. 33, Núm. 2, pp. 121-128

  2. PR-LncRNA signature regulates glioma cell activity through expression of SOX factors

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. MTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance

    Expert Opinion on Therapeutic Targets, Vol. 20, Núm. 4, pp. 393-405

  2. Targeting SOX2 as a therapeutic strategy in glioblastoma

    Frontiers in Oncology

2013

  1. Therapeutic strategies targeting Glioblastoma stem cells

    Recent Patents on Anti-Cancer Drug Discovery, Vol. 8, Núm. 3, pp. 216-227

2012

  1. Funciones y organización de un comité de neurooncologí a en un hospital con servicio de neurocirugía

    Neurocirugia, Vol. 23, Núm. 4, pp. 151-156

2005

  1. Aspergillus granuloma of the cavernous sinus: magnetic resonance imaging with pathologic correlation.

    Acta neurochirurgica, Vol. 147, Núm. 3